Jing Zhou

Jing Zhou

Auto-generated profile, based on publicly available information

Jing Zhou

Department of Respiratory Medicine, The First Affiliated Hospital of Nanchang University, Nanchang, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2018 in BioMed Research International
Verified
Journal Article
Open access
JZJing Zhou
Jing Zhou
WBWei Bai
Wei Bai
QLQin Liu
Qin Liu
JCJian Cui
Jian Cui
WZWei Zhang
Wei Zhang
Intermittent hypoxia (IH) that resulted from obstructive sleep apnea (OSA) has been found to be a risk factor of coronary artery disease. IH and the receptor for advanced glycation end products (RAGE) expression are known to activate monocyte/macrophage and associated with atherosclerosis development, while their effects on monocyte adhesion, chemotaxis to the endothelium, and macrophage polarization remain unknown. In the present study, RAGE in THP-1 monocytes was inhibited by shRNA lentiviral particles, followed by exposure to IH. Cell adhesion assay, transwell migration assay, and macrophage polarization assays were performed to study the effects of IH and RAGE. The mRNA and protein expression levels were investigated by RT/real-time PCR and western blot analysis, respectively. We found that IH increased RAGE expression and activated NF-кB signalling in THP-1 monocytes. The results also revealed that IH enhanced the MCP-1-mediated THP-1 monocyte adhesion and chemotaxis and promoted macrophage polarization toward a proinflammatory phenotype, which was mediated by RAGE activity. Additionally, inhibition of chemokine receptor type 2 (CCR2) suppressed the IH-induced monocyte adhesion and chemotaxis. These results demonstrated a potential role of monocyte adhesion, chemotaxis, and macrophage polarization in the development cardiovascular diseases induced by IH and identified that RAGE could be a promising therapeutic target to prevent atherosclerosis in patients with OSA.

15 June 2009 in Cancer Biology & Therapy
Verified
Journal Article
Open access
ASAndrew R Snyder
Andrew R Snyder
JZJing Zhou
Jing Zhou
ZDZhong Deng
Zhong Deng
PLPaul Lieberman
Paul Lieberman
Hydroxyurea (HU) is a chemotherapeutic agent commonly used for various malignancies and hematological disorders, including chronic myelogenous leukemia and sickle cell anemia. We show here that chr...

1 September 2016 in Journal of Immunological Methods
Verified
Journal Article
Closed access
SCShang-Liang Chen
Shang-Liang Chen
YLYan-Li Li
Yan-Li Li
YTYuan Tang
Yuan Tang
ZCZhi-Cheng Chen
Zhi-Cheng Chen
JZJing Zhou
Jing Zhou
DZDaming Zuo
Daming Zuo